^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners

    TEST:
    NVIGEN X™

    Company:
    NVIGEN
    Type:
    Laboratory Developed Test
    Details
    Evidence

    News

    1year
    NVIGEN unveils groundbreaking comprehensive liquid biopsy at San Antonio Breast Cancer Symposium: Advancing clinical utility with multimodal biomarker detection enabled by highly versatile nanoparticle capture (PRNewswire)
    "NVIGEN...unveil its groundbreaking technology, NVIGEN X®-Precision Medicine Biomarker Profiling, at the San Antonio Breast Cancer Symposium from December 5 to 9."
    Clinical data
    |
    NVIGEN X™
    1year
    NVIGEN X® Comprehensive Liquid Biopsy for Sensitive ctDNA, Circulating Tumor Cells (CTC), and Protein Detection in Breast Cancer: Next-Generation Sequencing, Patient Case Studies, and Clinical Implications (SABCS 2023)
    Conclusions The analysis of the presented data from 36 patient samples with advanced breast cancer highlight the clinical relevance and potential significance of utilizing ctDNA, CTC and protein biomarkers in monitoring disease dynamics, treatment response, and guiding personalized treatment approaches. Our results suggest that individual protein biomarker analysis may be crucial in supporting personalized diagnostics and enabling more effective personalized medicine strategies.
    Clinical • Circulating tumor cells • Liquid biopsy • Next-generation sequencing • Circulating tumor DNA • Tumor cell • Biopsy
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha)
    |
    NVIGEN X™
    3years
    Nvigen circulating tumor DNA assay shows high NGS data efficiency in quality control study (Genomeweb)
    "Nvigen...presented data last week at the San Antonio Breast Cancer Symposium showing that its Nvigen X Cancer Precision Profiling assay accurately monitors dynamic changes in circulating tumor DNA, or ctDNA...In a poster presented at SABCS, Nvigen showed performance metrics data of Nvigen X and a case study from an ongoing 150-person pilot study of the assay's performance in breast cancer patients."
    Clinical data
    |
    NVIGEN X™